Work

Supplementary Table S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table S2 shows type I and II MET kinase inhibitors and key trials studying their activity lung cancer populations enriched for MET-dependence.

DOI: 10.1158/2159-8290.22531684.v1

Authors: Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine A. Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362481445

Cites:

Cited by:

Related to: 10